CNTX
Context Therapeutics Inc.
Biotechnology
Market Cap$214M
5Y Perf.+23.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CNTX vs ONCO
Revenue, margins, valuation, and 5-year total return — side by side.
ONCO
Onconetix, Inc.
Biotechnology
Market Cap$1M
5Y Perf.-100.0%
CNTX vs ONCO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CNTX | ONCO |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $214M | $1M |
| Revenue (TTM) | $0.00 | $815K |
| Net Income (TTM) | $-40M | $-14M |
| Gross Margin | — | 77.6% |
| Operating Margin | — | -21.9% |
| Total Debt | $112K | $49K |
| Cash & Equiv. | $66M | $5M |
CNTX vs ONCO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CNTX
ONCO
| Stock | Feb 22 | May 26 | Return |
|---|---|---|---|
| Context Therapeutic… (CNTX) | 100 | 123.9 | +23.9% |
| Onconetix, Inc. (ONCO) | 100 | 0.0 | -100.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CNTX vs ONCO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CNTX leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Onconetix, Inc. is the stronger pick specifically for dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
CNTX
Context Therapeutics Inc.
The Income Pick
CNTX carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.46
- -54.3% 10Y total return vs ONCO's -100.0%
- Lower volatility, beta 0.46, Low D/E 0.2%, current ratio 8.52x
Best for: income & stability and long-term compounding
ONCO
Onconetix, Inc.
The Growth Play
ONCO is the clearest fit if your priority is growth exposure.
- Rev growth -67.7%, EPS growth 99.1%
- 30.9% yield; the other pay no meaningful dividend
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CNTX | -45.5% revenue growth vs ONCO's -67.7% |
| Quality / Margins | CNTX | 4.9% margin vs ONCO's -17.2% |
| Stability / Safety | CNTX | Beta 0.46 vs ONCO's 1.41, lower leverage |
| Dividends | ONCO | 30.9% yield; the other pay no meaningful dividend |
| Momentum (1Y) | CNTX | +201.4% vs ONCO's -98.6% |
| Efficiency (ROA) | CNTX | -54.8% ROA vs ONCO's -68.0% |
CNTX vs ONCO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
CNTX vs ONCO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCNTXLAGGINGONCO
ONCOOnconetix, Inc.
1leads
CNTXContext Therapeutics …
3leads
6 Total Categories
CATEGORYLEADERvs ONCOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ONCO1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CNTX4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
CNTX6/6
Risk & VolatilityBeta, volatility, and downside exposure
CNTX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ONCO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ONCO and CNTX operate at a comparable scale, with $815,371 and $0 in trailing revenue.
| Metric | CNTXContext Therapeut… | ONCOOnconetix, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $815,371 |
| EBITDAEarnings before interest/tax | -$43M | -$18M |
| Net IncomeAfter-tax profit | -$40M | -$14M |
| Free Cash FlowCash after capex | -$21M | -$10M |
| Gross MarginGross profit ÷ Revenue | — | +77.6% |
| Operating MarginEBIT ÷ Revenue | — | -21.9% |
| Net MarginNet income ÷ Revenue | — | -17.2% |
| FCF MarginFCF ÷ Revenue | — | -11.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -57.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -80.0% | +120.9% |
ONCO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — CNTX and ONCO each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | CNTXContext Therapeut… | ONCOOnconetix, Inc. |
|---|---|---|
| Market CapShares × price | $214M | $1M |
| Enterprise ValueMkt cap + debt − cash | $148M | -$4M |
| Trailing P/EPrice ÷ TTM EPS | -6.13x | -0.09x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 1.70x |
| Price / BookPrice ÷ Book value/share | 3.67x | 0.08x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — CNTX and ONCO each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
CNTX leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
CNTX delivers a -60.0% return on equity — every $100 of shareholder capital generates $-60 in annual profit, vs $-190 for ONCO. CNTX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to ONCO's 0.00x. On the Piotroski fundamental quality scale (0–9), ONCO scores 5/9 vs CNTX's 3/9, reflecting solid financial health.
| Metric | CNTXContext Therapeut… | ONCOOnconetix, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -60.0% | -189.8% |
| ROA (TTM)Return on assets | -54.8% | -68.0% |
| ROICReturn on invested capital | — | -32.8% |
| ROCEReturn on capital employed | -50.9% | -49.4% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | 0.00x | 0.00x |
| Net DebtTotal debt minus cash | -$66M | -$5M |
| Cash & Equiv.Liquid assets | $66M | $5M |
| Total DebtShort + long-term debt | $112,064 | $48,774 |
| Interest CoverageEBIT ÷ Interest expense | — | -26.95x |
CNTX leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
CNTX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CNTX five years ago would be worth $4,569 today (with dividends reinvested), compared to $0 for ONCO. Over the past 12 months, CNTX leads with a +201.4% total return vs ONCO's -98.6%. The 3-year compound annual growth rate (CAGR) favors CNTX at 56.7% vs ONCO's -97.2% — a key indicator of consistent wealth creation.
| Metric | CNTXContext Therapeut… | ONCOOnconetix, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +50.3% | -95.0% |
| 1-Year ReturnPast 12 months | +201.4% | -98.6% |
| 3-Year ReturnCumulative with dividends | +285.1% | -100.0% |
| 5-Year ReturnCumulative with dividends | -54.3% | -100.0% |
| 10-Year ReturnCumulative with dividends | -54.3% | -100.0% |
| CAGR (3Y)Annualised 3-year return | +56.7% | -97.2% |
CNTX leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
CNTX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CNTX is the less volatile stock with a 0.46 beta — it tends to amplify market swings less than ONCO's 1.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CNTX currently trades 64.4% from its 52-week high vs ONCO's 0.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CNTXContext Therapeut… | ONCOOnconetix, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.46x | 1.41x |
| 52-Week HighHighest price in past year | $3.62 | $74.30 |
| 52-Week LowLowest price in past year | $0.49 | $0.37 |
| % of 52W HighCurrent price vs 52-week peak | +64.4% | +0.5% |
| RSI (14)Momentum oscillator 0–100 | 48.4 | 28.8 |
| Avg Volume (50D)Average daily shares traded | 901K | 9.4M |
CNTX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
ONCO is the only dividend payer here at 30.89% yield — a key consideration for income-focused portfolios.
| Metric | CNTXContext Therapeut… | ONCOOnconetix, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $5.25 | — |
| # AnalystsCovering analysts | 6 | — |
| Dividend YieldAnnual dividend ÷ price | — | +30.9% |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | $0.12 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CNTX leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). ONCO leads in 1 (Income & Cash Flow). 1 tied.
Best OverallContext Therapeutics Inc. (CNTX)Leads 3 of 6 categories
Loading custom metrics...
CNTX vs ONCO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CNTX or ONCO a better buy right now?
Analysts rate Context Therapeutics Inc.
(CNTX) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CNTX or ONCO?
Over the past 5 years, Context Therapeutics Inc.
(CNTX) delivered a total return of -54. 3%, compared to -100. 0% for Onconetix, Inc. (ONCO). Over 10 years, the gap is even starker: CNTX returned -54. 3% versus ONCO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CNTX or ONCO?
By beta (market sensitivity over 5 years), Context Therapeutics Inc.
(CNTX) is the lower-risk stock at 0. 46β versus Onconetix, Inc. 's 1. 41β — meaning ONCO is approximately 207% more volatile than CNTX relative to the S&P 500. On balance sheet safety, Context Therapeutics Inc. (CNTX) carries a lower debt/equity ratio of 0% versus 0% for Onconetix, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CNTX or ONCO?
On earnings-per-share growth, the picture is similar: Onconetix, Inc.
grew EPS 99. 1% year-over-year, compared to 17. 4% for Context Therapeutics Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CNTX or ONCO?
Context Therapeutics Inc.
(CNTX) is the more profitable company, earning 0. 0% net margin versus -1721. 0% for Onconetix, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CNTX leads at 0. 0% versus -778. 2% for ONCO. At the gross margin level — before operating expenses — ONCO leads at 77. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CNTX or ONCO?
In this comparison, ONCO (30.
9% yield) pays a dividend. CNTX does not pay a meaningful dividend and should not be held primarily for income.
07Is CNTX or ONCO better for a retirement portfolio?
For long-horizon retirement investors, Context Therapeutics Inc.
(CNTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 46)). Both have compounded well over 10 years (CNTX: -54. 3%, ONCO: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CNTX and ONCO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CNTX is a small-cap quality compounder stock; ONCO is a small-cap income-oriented stock. ONCO pays a dividend while CNTX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.